1. R-CHOP versus R-COMP: Are They Really Equally Effective?
- Author
-
Mian, M., Wasle, I., Gamerith, G., Mondello, P., Melchardt, T., Jäger, T., Linkesch, W., and Fiegl, M.
- Subjects
- *
ANTINEOPLASTIC agents , *ACADEMIC medical centers , *B cell lymphoma , *MEDICAL records , *RETROSPECTIVE studies - Abstract
The first-line standard treatment for diffuse large B-cell lymphoma (DLBCL) is the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). It is associated with cardiotoxicity, which is why new treatment strategies are needed. Liposomial doxorubicin has been proven to reduce these side-effects, but until now a direct comparison regarding efficacy has not yet been published. We retrospectively assessed 364 consecutive DLBCL patients who underwent either R-CHOP (218; 60%) or R-COMP (doxorubicin replaced by non-pegylated liposomal doxorubicin; 146; 40%) in first line and compared outcome and survival. We provide evidence that both regimens induce a high and comparable number of complete remissions and that both are able to cure patients with DLBCL. Confirmatory data are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF